A GCN1-independent activator of the kinase GCN2

Abstract Mutations of EIF2AK4 , which encodes the eIF2α kinase GCN2, cause a severe inherited form of pulmonary hypertension called pulmonary veno-occlusive disease (PVOD). Some pathogenic variants of GCN2 are amenable to pharmacological reactivation by low concentrations of ATP-pocket binding inhibitors. Kinase inhibition at modestly elevated concentrations limits the clinical utility of these drugs against PVOD. We therefore performed an in cellulo chemical screen for GCN2 activators and identified three structurally distinct compounds with low micromolar stimulatory activities. Unlike previously described GCN2 activators, one of these molecules activated GCN2 independently of GCN1. Modelling supported by structure activity screens suggested it binds within the ATP-pocket of GCN2, but unlike existing ligands does not protrude inward into the allosteric pocket or outward into the solvent. This overcomes a key requirement of other GCN2 activators.

Authors

Institutions

Publication Details

Journal
eLife
Published
2026-10-27
DOI
https://doi.org/10.7554/elife.108590.3
Citations
1
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
4.78

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A GCN1-independent activator of the kinase GCN2

Joseph E. Chambers, Aldo S. Bader, Henriëtte M. G. Willems, Nicholas W. Morrell et al.
1 citations
eLife
Pulmonary Hypertension Research and Treatments
4.78
article

A GCN1-independent activator of the kinase GCN2

Joseph E. Chambers, Aldo S. Bader, Henriëtte M. G. Willems, Nicholas W. Morrell, Giulia Emanuelli, Vanesa Vinciauskaite, Jordan Wilson, Glenn Robert Masson, Stefan John Marciniak, John Skidmore, Jiayi Zhu
article en
1 citations

Abstract

Abstract Mutations of EIF2AK4 , which encodes the eIF2α kinase GCN2, cause a severe inherited form of pulmonary hypertension called pulmonary veno-occlusive disease (PVOD). Some pathogenic variants of GCN2 are amenable to pharmacological reactivation by low concentrations of ATP-pocket binding inhibitors. Kinase inhibition at modestly elevated concentrations limits the clinical utility of these drugs against PVOD. We therefore performed an in cellulo chemical screen for GCN2 activators and identified three structurally distinct compounds with low micromolar stimulatory activities. Unlike previously described GCN2 activators, one of these molecules activated GCN2 independently of GCN1. Modelling supported by structure activity screens suggested it binds within the ATP-pocket of GCN2, but unlike existing ligands does not protrude inward into the allosteric pocket or outward into the solvent. This overcomes a key requirement of other GCN2 activators.

eLifeVol. 14
Babraham Institute (GB), University of Cambridge (GB), Cancer Research UK (GB), Ninewells Hospital (GB), Papworth Hospital NHS Foundation Trust (GB), Domainex (United Kingdom) (GB)
Royal Papworth Hospital NHS Foundation Trust, University of Dundee, UK Research and Innovation, British Heart Foundation, British Lung Foundation, Asthma and Lung UK, Tenovus, University of Cambridge, Cambridge Trust, Evelyn Trust, Directorate for Biological Sciences, Medical Research Council, Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, Cambridge Institute for Medical Research, University of Cambridge, NIHR Cambridge Biomedical Research Centre
Good health and well-being
Openalex Percentile: Top 11%
Pulmonary Hypertension Research and Treatments
4.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon